Literature DB >> 34767055

Spectrum of B-cell neoplasms associated with immunoglobulin G4-related disease.

Ryan C W Ho1, Thomas S Y Chan1, Rex Au-Yeung2, Karen H K Tang1, Yu-Yan Hwang1, Eric Tse1, Yok-Lam Kwong3.   

Abstract

Immunoglobulin G4-related disease (IgG4-RD) has rarely been associated with lymphoid neoplasms, the spectrum of which remains unclear. B-cell lymphoid neoplasms (LN) associated with IgG4-RD diagnosed in a 4-year period were analysed. There were five men and three women at a median age of 76.5 (52-90) years; three with synchronous IgG4-RD and LN; three with IgG4-RD preceding LN by 2, 3, and 22 years; and two with LN preceding IgG4-RD by 2.5 and 7 years. All patients presented with disseminated lymphadenopathy. Monoclonal gammopathy of undetermined significance (MGUS)/smouldering multiple myeloma (SMM) was found in three patients, all with an IgGκ paraprotein. Levels of IgGκ and IgG4 correlated. Diffuse large B-cell lymphoma (DLBCL) was found in three patients, with one case showing co-existing lymphoma and IgG4-RD in the same lymph node biopsy. The remaining two cases were marginal zone lymphoma (MZL) developing in a lacrimal gland previously involved by IgG4-RD; and nodular lymphocyte predominant Hodgkin lymphoma (NLP-HL) diagnosed in a lymph node with concomitant IgG4-RD. Low-dose continuous prednisolone was given for MGUS/SMM, with both monoclonal IgGκ and IgG4 responding. Combination chemotherapy was given for DLBCL, with two patients achieving complete response and one patient dying from refractory lymphoma. The patient with MZL refused treatment, whereas the case of NLP-HL responded completely to chemotherapy. Our findings together with previous observations suggest that IgG4-RD has an increased risk of B-cell neoplasms. Patients with IgG4-RD presenting with lymphadenopathy require vigorous investigations to exclude lymphoid neoplasms.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Diffuse large B-cell lymphoma; IgG4-related disease; Marginal zone lymphoma; Monoclonal gammopathy of undetermined significance

Mesh:

Substances:

Year:  2021        PMID: 34767055     DOI: 10.1007/s00277-021-04675-w

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  46 in total

Review 1.  IgG4-related disease.

Authors:  John H Stone; Yoh Zen; Vikram Deshpande
Journal:  N Engl J Med       Date:  2012-02-09       Impact factor: 91.245

Review 2.  Consensus statement on the pathology of IgG4-related disease.

Authors:  Vikram Deshpande; Yoh Zen; John Kc Chan; Eunhee E Yi; Yasuharu Sato; Tadashi Yoshino; Günter Klöppel; J Godfrey Heathcote; Arezou Khosroshahi; Judith A Ferry; Rob C Aalberse; Donald B Bloch; William R Brugge; Adrian C Bateman; Mollie N Carruthers; Suresh T Chari; Wah Cheuk; Lynn D Cornell; Carlos Fernandez-Del Castillo; David G Forcione; Daniel L Hamilos; Terumi Kamisawa; Satomi Kasashima; Shigeyuki Kawa; Mitsuhiro Kawano; Gregory Y Lauwers; Yasufumi Masaki; Yasuni Nakanuma; Kenji Notohara; Kazuichi Okazaki; Ji Kon Ryu; Takako Saeki; Dushyant V Sahani; Thomas C Smyrk; James R Stone; Masayuki Takahira; George J Webster; Motohisa Yamamoto; Giuseppe Zamboni; Hisanori Umehara; John H Stone
Journal:  Mod Pathol       Date:  2012-05-18       Impact factor: 7.842

Review 3.  IgG4-related disease.

Authors:  Terumi Kamisawa; Yoh Zen; Shiv Pillai; John H Stone
Journal:  Lancet       Date:  2014-12-04       Impact factor: 79.321

4.  Association of IgG4-Related Disease With History of Malignancy.

Authors:  Zachary S Wallace; Carly J Wallace; Na Lu; Hyon K Choi; John H Stone
Journal:  Arthritis Rheumatol       Date:  2016-09       Impact factor: 10.995

Review 5.  Advances in the diagnosis and management of IgG4 related disease.

Authors:  Marco Lanzillotta; Gaia Mancuso; Emanuel Della-Torre
Journal:  BMJ       Date:  2020-06-16

Review 6.  The 2016 revision of the World Health Organization classification of lymphoid neoplasms.

Authors:  Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe
Journal:  Blood       Date:  2016-03-15       Impact factor: 22.113

Review 7.  International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

Authors:  S Vincent Rajkumar; Meletios A Dimopoulos; Antonio Palumbo; Joan Blade; Giampaolo Merlini; María-Victoria Mateos; Shaji Kumar; Jens Hillengass; Efstathios Kastritis; Paul Richardson; Ola Landgren; Bruno Paiva; Angela Dispenzieri; Brendan Weiss; Xavier LeLeu; Sonja Zweegman; Sagar Lonial; Laura Rosinol; Elena Zamagni; Sundar Jagannath; Orhan Sezer; Sigurdur Y Kristinsson; Jo Caers; Saad Z Usmani; Juan José Lahuerta; Hans Erik Johnsen; Meral Beksac; Michele Cavo; Hartmut Goldschmidt; Evangelos Terpos; Robert A Kyle; Kenneth C Anderson; Brian G M Durie; Jesus F San Miguel
Journal:  Lancet Oncol       Date:  2014-10-26       Impact factor: 41.316

Review 8.  Elements of cancer immunity and the cancer-immune set point.

Authors:  Daniel S Chen; Ira Mellman
Journal:  Nature       Date:  2017-01-18       Impact factor: 49.962

Review 9.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

Review 10.  The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease.

Authors:  Zachary S Wallace; Ray P Naden; Suresh Chari; Hyon K Choi; Emanuel Della-Torre; Jean-Francois Dicaire; Phillip A Hart; Dai Inoue; Mitsuhiro Kawano; Arezou Khosroshahi; Marco Lanzillotta; Kazuichi Okazaki; Cory A Perugino; Amita Sharma; Takako Saeki; Nicolas Schleinitz; Naoki Takahashi; Hisanori Umehara; Yoh Zen; John H Stone
Journal:  Ann Rheum Dis       Date:  2019-12-03       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.